Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care
Liver International · 2025-10 · 45 (10)
DOI: 10.1111/liv.70311 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 17.09.2025. Verfasst von Zobair M Younossi und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Global MASH Council, Washington, DC, USA. Hauptthemen laut MEDLINE: Public Health, Precision Medicine, Health Care Reform, Fatty Liver. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 112 Literaturangaben. Gefördert von: The Global NASH Council, Novo Nordisk Fonden, Siemens.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is growing in prevalence around the world, with a current global prevalence rate of 38%. Although MASLD serves as an umberlla term, its subtype of metabolic dysfunction associated steatohepatitis (MASH) with a prevalence of 5‐7%, can lead to adverse liver outcomes including cirrhosis and liver mortality. However, prevalence rates for MASLD/MASH vary by country and region of the world. With the increasing rates of type 2 diabetes and obesity, MASLD/MASH is increasing and is currently among the top causes of hepatocellular carcinoma and an indication for liver transplantation in the United States. Therefore, the care model is shifting to prevention given this large clinical, economic and humanistic burden of this liver disease. As in other noncommunicable diseases, interventional priorities for policymakers should be focused on building infrastructure that supports physical activity and healthy food choices as well as access to approved treatments for MASLD. At the same time, identifying individuals at risk for adverse outcomes using non‐invasive tests and developing individual care plans that address the needs of each patient with MASLD, including their mental and physical health, should be a focus for healthcare providers. Furthermore, raising awareness among patients, the public and healthcare providers continues to be a crucial need. This report will provide recommendations for policymakers to provide the needed interventions to reverse the current trajectory of this liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Global MASH Council, Washington, DC, USA.
- Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
- Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
- UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK.
- Department of Hepatology, Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France.
- Fatty Liver Alliance, Toronto, Ontario, Canada.
ORCID-Profile: Zobair M Younossi, Vincent Wai-Sun Wong, Linda Henry, Shira Zelber Sagi
Förderung
- The Global NASH Council
- Novo Nordisk Fonden
- Siemens
Zitieren
APA
Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castera, L., Betel, M., Henry, L., & Sagi, S. Z. (2025). Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care. Liver International, 45(10). https://doi.org/10.1111/liv.70311
Vancouver
Younossi ZM, Wong VW, Tsochatzis EA, Castera L, Betel M, Henry L, et al. Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care. Liver International. 2025;45(10). doi:10.1111/liv.70311
BibTeX
@article{Younossi2025,
author = {Younossi, Zobair M and Wong, Vincent Wai-Sun and Tsochatzis, Emmanuel A and Castera, Laurent and Betel, Michael and Henry, Linda and Sagi, Shira Zelber},
title = {Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care},
journal = {Liver International},
year = {2025},
volume = {45},
number = {10},
doi = {10.1111/liv.70311}
}
EUVIMED